PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
To assess the safety and effectiveness of PBF-1681 for the treatment of Iron Deficiency
Anemia in patients with Non-Dialysis Dependent Chronic Kidney Disease.